Publish date:

Alteryx, Group 1 Automotive: 5 Top Stock Gainers for Tuesday

Alteryx, Group 1 Automotive, Endo International, Chromadex and Kiniksa Pharmaceuticals are some of Tuesday's top stock gainers.

Stocks finished sharply lower Tuesday after President Donald Trump told his team to halt negotiations with Democrats on a fiscal stimulus package.

Here are some of the top stock gainers for Tuesday

1. Alteryx | Percentage Increase 28%

Alteryx  (AYX) - Get Alteryx, Inc. Class A Report shares jumped after the data-analytics-software company raised its sales outlook and named a new CEO. Mark Anderson, a current board member, is succeeding co-founder Dean Stoecker.

2. Group 1 Automotive | Percentage Increase 16%

Group 1 Automotive  (GPI) - Get Group 1 Automotive, Inc. Report climbed after the auto retailer offered positive guidance for the third quarter, announced a new $200 million share buyback program and said it would reinstate its quarterly cash dividend, which had been suspended during the pandemic. 

TheStreet Recommends

3. Endo International | Percentage Increase 14%

Endo International  (ENDP) - Get Endo International Plc Report rose a day after Piper Sandler analyst David Amsellem reiterated an overweight rating on shares of the pharmaceutical company with a $5 price target. Seventy-three percent of dermatologists surveyed said they planned to offer Endo's Qwo to a majority of their patients with cellulite to the extent that it is priced reasonably relative to minimally invasive technologies.

4. ChromaDex | Percentage Increase 27%

ChromaDex  (CDXC) - Get ChromaDex Corporation Report advanced after the biotech said the results of a Phase 2 study found that patients with mild-to-moderate coronavirus experienced a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including the company's nicotinamide riboside.

5. Kiniksa Pharmaceuticals | Percentage Increase 18%

Kiniksa Pharmaceuticals  (KNSA) - Get Kiniksa Pharmaceuticals Ltd. Class A Report gained after the drugmaker announced positive data from a mid-stage study of its mavrilimumab in giant cell arteritis, an inflammatory disease affecting the large blood vessels of the scalp, neck and arms.